Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 3/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.45 |
| ▸ | PPARD | Q03181 | 3/20 | 0.45 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | FABP4 | P15090 | 2/20 | 0.45 |
| ▸ | TOP1 | P11387 | 2/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28049691 | 1.00 | EP300 (0.57) | EP300TSHRFAAHTRPV1TERT | |
| SCHEMBL289331 | 1.00 | EP300 (0.57) | EP300TSHRFAAHTRPV1TERT | |
| SCHEMBL29186895 | 1.00 | EP300 (0.57) | EP300TSHRFAAHTRPV1TERT | |
| SCHEMBL15365004 | 0.98 | EP300 (0.54) | EP300TSHRFAAHTRPV1TERT | |
| SCHEMBL15365002 | 0.98 | EP300 (0.54) | EP300TSHRFAAHTRPV1TERT | |
| Pyrrole SCHEMBL989904 | 0.87 | EP300 (0.46) | EP300TSHRFAAHTRPV1TERT | |
| Pyrrole SCHEMBL989906 | 0.87 | EP300 (0.46) | EP300TSHRFAAHTRPV1TERT | |
| SCHEMBL1270472 | 0.80 | — | — | |
| SCHEMBL1270469 | 0.80 | — | — | |
| SCHEMBL6577157 | 0.79 | EP300 (0.50) | EP300TSHRFAAHTRPV1TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 598 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113784629-B | Method for preparing plant extract composition | 嘉吉公司 | 2024-12-27 | — | — | CN | claimed |
| EP-4363043-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2024-05-08 | — | — | EP | claimed |
| US-11931391-B2 | Methods for making botanical extract composition | CARGILL, INCORPORATED (US) | 2024-03-19 | — | — | US | claimed |
| CN-117580614-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2024-02-20 | — | — | CN | claimed |
| US-20230364270-A1 | LIPOSOME-ASSISTED IMAGING OF VASCULAR INFLAMMATION | HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ (FI) | 2023-11-16 | — | — | US | claimed |
| EP-4192520-A1 | LIPOSOME-ASSISTED IMAGING OF VASCULAR INFLAMMATION | Helsingin Ja Uudenmaan Sairaanhoitopiirin Kuntayhtymä (FI) | 2023-06-14 | — | — | EP | claimed |
| EP-4188380-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2023-06-07 | — | — | EP | claimed |
| CN-116096432-A | Liposome-assisted imaging of vascular inflammation | 赫尔辛基和乌登曼护理区市政协会 | 2023-05-09 | — | — | CN | claimed |
| US-20230001193-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | BIOPHARMA CREDIT PLC (GB) | 2023-01-05 | — | — | US | claimed |
| WO-2023275649-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2023-01-05 | — | — | WO | claimed |
| US-20050272094-A1 | Purified antigen for Alzheimer's disease and methods of obtaining and using same | MOLECULAR GERIATRICS CORPORATION | 2005-12-08 | — | — | US | claimed |
| WO-2005023864-A1 | PEPTIDE-BASED IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS | FORSKARPATENT I SYD AB (SE) | 2005-03-17 | — | — | WO | claimed |
| JP-2004529143-A | — | — | 2004-09-24 | — | — | JP | claimed |
| EP-1383526-A1 | PEPTIDE-BASED IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS AND DEVELOPMENT OF PEPTIDE-BASED ASSAY FOR DETERMINATION OF IMMUNE RESPONSES AGAINST OXIDIZED LOW DENSITY LIPOPROTEIN | Forskarpatent I SYD (SE) | 2004-01-28 | — | — | EP | claimed |
| US-20030113896-A1 | Purified antigen for Alzheimer's disease and methods of obtaining and using same | ZINKOWSKI RAYMOND P (US) | 2003-06-19 | — | — | US | claimed |
| US-20030105003-A1 | Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein | CARDIOVAX, LLC | 2003-06-05 | — | — | US | claimed |
| WO-2002080954-A1 | PEPTIDE-BASED IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS AND DEVELOPMENT OF PEPTIDE-BASED ASSAY FOR DETERMINATION OF IMMUNE RESPONSES AGAINST OXIDIZED LOW DENSITY LIPOPROTEIN | FORSKARPATENT I SYD (SE) | 2002-10-17 | — | — | WO | claimed |
| EP-1189937-A1 | PURIFIED ANTIGEN FOR ALZHEIMER'S DISEASE, AND METHODS OF OBTAINING AND USING SAME | MOLECULAR GERIATRICS CORPORATION (US) | 2002-03-27 | — | — | EP | claimed |
| US-20020002270-A1 | PURIFIED ANTIGEN FOR ALZHEIMER'S DISEASE, AND METHODS OF OBTAINING AND USING SAME | MOLECULAR GERIATRICS CORPORATION | 2002-01-03 | — | — | US | claimed |
| WO-2000078807-A1 | PURIFIED ANTIGEN FOR ALZHEIMER'S DISEASE, AND METHODS OF OBTAINING AND USING SAME | MOLECULAR GERIATRICS CORPORATION (US) | 2000-12-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105003-A1 | Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein | APOB, LDLR, APOL1 | EP300 4001/4885TSHR 2812/4885FAAH 3167/4885 |
| US-11931391-B2 | Methods for making botanical extract composition | ME1, SLC16A7, MCCC2 | EP300 2947/4885TSHR 4640/4885FAAH 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.